Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335064 | 0.99 | HTR2A (0.40) | HTR2ACCR3KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL6336559 | 0.93 | HTR2A (0.36) | HTR2ACCR3KCNH2MCHR1P2RX7 | |
| SCHEMBL6329161 | 0.92 | P2RX7 (0.40) | HTR2ACCR3KDM4ESMN1; SMN2P2RX7 | |
| SCHEMBL6331104 | 0.87 | P2RX7 (0.37) | HTR2ACCR3P2RX7HTR2CGPR6 | |
| SCHEMBL6328573 | 0.85 | NMT2 (0.41) | HTR2AP2RX7HTR2CACHEGPR6 | |
| SCHEMBL6336004 | 0.84 | P2RX7 (0.39) | HTR2AP2RX7HTR2CBCHEACHE | |
| SCHEMBL6336907 | 0.84 | P2RX7 (0.38) | HTR2ACCR3P2RX7GPR6 | |
| SCHEMBL6335068 | 0.83 | P2RX7 (0.35) | HTR2ACCR3P2RX7HTR2CGPR6 | |
| SCHEMBL6336600 | 0.83 | P2RX7 (0.40) | HTR2ACCR3P2RX7 | |
| SCHEMBL6329084 | 0.83 | NMT2 (0.37) | HTR2ACCR3P2RX7HTR2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | HTR2A 2694/4885CCR3 1359/4885KDM4E 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.